

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Tryptophan hydroxylase autoantibodies as markers of a distinct autoimmune gastrointestinal component of autoimmune polyendocrine syndrome type 1.

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/147735> since 2016-07-16T11:12:55Z

Published version:

DOI:10.1210/jc.2012-2734

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the author's final version of the contribution published as:

R.Scarpa; R. Alaggio; L. Norberto; J. Furmaniak; S. Chen; BR. Smith; S. Masiero; L. Morlin; M. Plebani; F. De Luca F; MC. Salerno; R. Giordano; G. Radetti; L. Ghizzoni; G. Tonini; F. Farinati; C. Betterle. Tryptophan hydroxylase autoantibodies as markers of a distinct autoimmune gastrointestinal component of autoimmune polyendocrine syndrome type 1.. THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. 98 (2) pp: 704-712.
DOI: 10.1210/jc.2012-2734

The publisher's version is available at:
<http://press.endocrine.org/doi/abs/10.1210/jc.2012-2734>

When citing, please refer to the published version.

Link to this full text:
<http://hdl.handle.net/2318/147735>

TRYPTOPHAN HYDROXYLASE AUTOANTIBODIES AS MARKERS OF A DISTINCT AUTOIMMUNE GASTROINTESTINAL COMPONENT OF AUTOIMMUNE POLYENDOCRINE SYNDROME TYPE 1

R. Scarpa, R. Alaggio, L. Norberto, J. Furmaniak, S. Chen, B. Rees Smith, S. Masiero, L. Morlin, M. Plebani, F. De Luca, M. C. Salerno, R. Giordano, G. Radetti, L. Ghizzoni, G. Tonini, F. Farinati, and C. Betterle

Department of Medicine (DIMED) (R.S., S.M., L.M., C.B.), University of Padua, Padua 35128, Italy; Department of Pathology (R.A.), University of Padua, Padua 35128, Italy; Department of Surgical and Gastroenterological Sciences (L.N.), First Surgical Clinic, Surgical Endoscopy Unit, University of Padua, Padua 35128, Italy; FIRS Laboratories (J.F., S.C., B.R.S), Cardiff CF14 5DU, United Kingdom; RSR Limited (B.R.S.), Cardiff CF23 8HE, United Kingdom; Department of Laboratory Medicine (M.P.), University of Padua, Padua 35128, Italy; Department of Pediatrics (F.D.L.), University of Messina, Messina 98124, Italy; Department of Pediatrics (M.C.S.), University “Federico II” of Naples, Naples 80138, Italy; Department of Clinical and Biological Sciences (R.G.), Division of Endocrinology, Diabetology and Metabolism, University of Turin, Turin 10125, Italy; Department of Pediatrics (G.R.), Regional Hospital of Bolzano, Bolzano 39100, Italy; Department of Internal Medicine (L.G.), Division of Endocrinology, Diabetology and Metabolism, University of Turin, Turin 10126, Italy; Department of Pediatrics (G.T.), Children Institute IRCCS “Burlo Garofolo,” University of Trieste, Trieste 34137, Italy; and Department of Surgical and Gastroenterological Sciences (F.F.), University of Padua, Padua 35128, Italy

Abbreviations: AIRE, Autoimmune regulator; APS-1, autoimmune-polyendocrine-syndrome type 1; EC, enterochromaffin cells; EE, enteroendocrine cells; GI, gastrointestinal; GID, gastrointestinal dysfunction; 5-HT, serotonin; IEL, intraepithelial lymphocytes; TPHAbs, tryptophan hydroxylase.

Abstract

Background: Autoantibodies to tryptophan hydroxylase (TPHAbs) directed against serotonin-producing enterochromaffin cells (EC) have been reported in autoimmune-polyendocrine-syndrome type 1 (APS-1) patients with

gastrointestinal dysfunction (GID). Serotonin plays a critical role in enteric function and its peripheral blood levels reflect serotonin release from the gastrointestinal tract.

Aims: We test the hypothesis that TPHAbs mark a distinct autoimmune component of APS-1 characterized by an autoimmune attack toward EC, which results in clinical GID.

Methods: TPHAbs were measured in 64 APS-1 patients. Endoscopy with gastric (antrum/body) and duodenal biopsy was carried in 16 TPHAbs+ patients (8 with and 8 without GID) and in 2 TPHAbs- patients (without GID). Immunohistochemistry of biopsy specimens was carried out using antibodies to serotonin, chromogranin-A, CD3, CD4, CD8, and CD20. Serotonin serum levels were measured in TPHAbs+ and TPHAbs- patients who had endoscopy.

Results: Thirty-seven of 64 patients were TPHAbs+ (11/12 with GID and 26/52 without GID; $P < .001$). Gastric and duodenal biopsies in all 8 TPHAb+ patients with GID showed lymphocytic infiltration with increased CD3+CD8+ intraepithelial lymphocytes and absence of EC. Furthermore, mean serotonin serum levels were below the normal range in TPHAb+ patients with GID ($P < .01$). In 8 TPHAb+ patients without GID gastric and duodenal biopsies showed different grades of inflammatory infiltration and reduced number of EC. Mean serotonin serum levels were near the lower limit of the normal range. In all TPHAbs+ patients the biopsies showed a reduced number of chromogranin-A positive cells consistent with enteroendocrine cells depletion. TPHAbs- patients without GID showed normal gastrointestinal mucosa and serotonin serum levels.

Conclusions: TPHAbs appear to be markers of a distinct autoimmune component of APS-1. Progressive involvement of the gastrointestinal EC leads to the transition from preclinical to clinical disease, characterized by GID and reduced serotonin serum levels.

Introduction

Autoimmune polyendocrine syndrome type 1 (APS-1) is a rare autosomal-recessive disorder caused by mutations in the autoimmune regulator (AIRE) gene (1, 2). APS-1 serves as a model of autoimmune disease in particular for understanding the relationship between the T-cell tolerance and the immune response against the self (3). The clinical phenotype is characterized by 3 main disease components (chronic mucocutaneous candidiasis, chronic hypoparathyroidism, and Addison's disease) often presenting together with other autoimmune diseases early in childhood and is associated with the presence of serum autoantibodies to different self-antigens (4 – 6).

Patients with APS-1 often present with gastrointestinal (GI) dysfunction (GID) that can be autoimmune (gastritis, hepatitis, idiopathic cholecystokinin deficiency, celiac disease) or nonautoimmune (cystic fibrosis, pancreatic insufficiency, lymphangectasia, and intestinal infections with *Candida albicans* or *Giardia lamblia*) or sometimes is classed as idiopathic (4 – 8). GI symptoms, such as recurrent diarrhea and steatorrhea or periodic or chronic constipation, can lead to malabsorption and cause reduction of the effectiveness of the replacement therapy in patients with deficiency of endocrine function (6).

It has been suggested that an autoimmune response directed to the enteroendocrine cells (EE) may be responsible for GID in a subset of patients with idiopathic GID (9 – 13). The EE cells represent the enteric endocrine system, secreting various GI peptides; these cells are scattered throughout the GI tract and are generally identified by chromogranin-A positivity by immunostaining on the tissue specimens. There are at least 15 subtypes of EE, secreting different peptide hormones that elaborately control physiological and homeostatic functions in the digestive tract, particularly postprandial secretion and motility. A set of biogenic amines are also synthesized and secreted, particularly serotonin (5-HT) from the diffusely distributed enterochromaffin cell (EC) (14).

It has been found that autoantibodies to tryptophan hydroxylase (TPH Abs) have been associated with the idiopathic form of GID in patients with APS-1 (9, 10).

Tryptophan hydroxylase is the rate-limiting enzyme in the synthesis of 5-HT and is expressed mainly in the EC of the gut. The release of 5-HT from EC initiates the activation of motor, secretory, and vasodilatory reflexes in response to luminal stimuli in the gut, and serotonin levels in the peripheral blood are thought to reflect serotonin release from the GI tract (15–20). To date the intestinal biopsies have been analyzed in only a few APS-1 patients with GID who were positive for TPH Abs and showed the absence of serotonin-containing EC but without the evidence of lymphocytic infiltration in the duodenal mucosa (9, 11, 21).

To test the hypothesis of an autoimmune attack toward EC further, we analyzed TPHAbs in 64 Italian patients with APS-1 and in 16 TPHAbs+ patients we measured serotonin plasma levels and examined GI biopsies using standard histological and immunohistochemical techniques.

Materials and Methods

Patients

We investigated 64 Italian patients with APS-1 (42 female and 22 male patients; mean age 33.7 y; range 7–76 y). Idiopathic GID was diagnosed in patients with recurrent chronic diarrhea with malabsorption and weight loss without any significant allergic, immunologic, infectious, and metabolic cause, or chronic constipation. Constipation and diarrhea periods were determined using patients records (in case of hospitalization) or obtained by interviewing the patients or their endocrinologist/pediatrician. According to stool frequency and/or consistency, defecation less than 3 times per week or hard, lumpy stool was defined as constipation, whereas defecation more than 3 times a day or soft, watery stool was defined as diarrhea.

Exocrine pancreatitis was ruled out because of the absence clinical signs or symptoms (no obstructive jaundice or abdominal pain) and normal serum amylase and lipase.

Twelve of 64 patients had idiopathic GID (18.8%; 5 male and 7 female patients; mean age 22.7 y; range 9–32 y) with mean onset at 10.6 years of age.

A gastroduodenal endoscopy including biopsies of gastric (antrum and body) and duodenal mucosa was carried out in 8 TPHAbs+ patients with GID (when symptomatic) and in 8 TPHAbs+ patients without GID. In addition, colonic biopsies were available for 3 patients (2 with and 1 without GID; Table 3, patients 4, 7, 15). The investigation was offered to all TPHAbs+ patients and to 10 TPHAbs- patients (with or without GID): patients' personal agreement was the only criteria of selection.

Six archival samples of normal gastric and duodenal mucosa and samples obtained from 2 TPHAbs- patients with APS-1 were used for reference.

Written informed consent was obtained from all patients and the study was approved by the local ethic committee.

TPHAb assays

TPHAbs were detected in serum samples by immunoprecipitation assay with ³⁵S-labeled full-length TPH, as described previously (10), and the upper normal limit of the antibody index was 2.3. Sera from 60 healthy blood donors were analyzed as controls.

Histology and immunohistochemistry

Biopsies were formalin-fixed and paraffin-embedded and sections were stained with hematoxylin and eosin and the modified Giemsa stain (for gastric biopsies alone) to identify *Helicobacter pylori* infection (22). The modified Sydney System was used to grade and stage the gastric biopsies (22). In addition, duodenal sections were assessed for villus-crypt ratio, lamina propria inflammation (quantified as normal or increased), and the presence of intraepithelial lymphocytes (IELs) (23).

Immunohistochemical tests were carried out by standard techniques using commercially available antibodies to serotonin (Novocastra, Newcastle, United Kingdom), chromogranin-A (Dako, Glostrup, Denmark), CD3 and CD4 (Novocastra), and CD8 and CD20 (Dako), according to the manufacturers' protocols.

Quantitative chromogranin-A and serotonin immunohistochemistry results were obtained by counting the number of positive cells in an area of mucosa bounded by 50 crypts (the given number of positive cells is the mean of positive cells counted in at least 3 different microscopic fields for each evaluation). Six archival samples of normal gastric and duodenal mucosa and samples obtained from 2 TPHAbs patients with APS-1 without GID were used to establish a normal mean and SD for our study. According to previous studies (24, 25), a count value 2 SDs below the mean of controls was defined as marked reduction of EE or EC cells. One SD below the mean was considered borderline reduction. The pathologist read the samples and was blinded to the status of the patient regarding GID and the presence of TPHAbs.

Serotonin serum levels

Patients and controls were tested in the morning after an overnight fast. Serotonin-rich foods, such as walnut, banana, aubergine, tomato, hazelnut, peanut, and avocado, were stopped 72 hours before the study. Drugs that modify GI function or the 5-HT system (analgesics, tranquilizers, or antidepressants) and cigarette smoking were forbidden 48 hours before the study, and alcohol and caffeine were ceased 24 hours before the study. All venous blood samples (2–4 mL) were drawn into plastic vacuum tubes. Serum was separated by centrifugation of the blood sample at 3000g for 15 minutes at room temperature and stored at

-20°C until assayed.

Serotonin serum levels were measured in the 16 TPHAbs+ patients who agreed to undergo endoscopy using liquid chromatography and electrochemical detection (26). The reproducibility of all the tests was satisfactory, the coefficient of analytical variation (interassay CV) being <7% for all concentrations of control materials. The normal range was 0.28 – 1.7 µmol/L, obtained from 40 healthy controls samples. As controls were also tested, 10 APS-1 patients were negative for TPHAbs and without GI symptoms.

Genetic study

All 14 exons of the AIRE gene were analyzed for mutations in the patients with APS-1, as described previously (27).

Statistical analysis

Fisher's exact test and Wilcoxon test were used for statistical evaluation in APS-1 patients.

Results

Patients

The clinical manifestations of APS-1 and the prevalence of disease components in the 64 APS-1 patients and in the 16 TPHAbs+ patients who consented to have an endoscopic study are shown in Table 1.

Diagnosis of each disease was based on typical clinical, immunologic, and biochemical grounds. Each APS-1 patient presented at least 2 of the 3 main diseases (chronic mucocutaneous candidiasis, chronic hypoparathyroidism, and Addison disease) (6). Furthermore, we tested 51 of 64 APS-1 patients for interferon- γ and 47 (92.2%) were positive. Three of the 4 negative patients carry an AIRE gene mutation in homozygosis or compound heterozygosis. The only patient interferon- γ -negative and without any detectable AIRE gene mutation was a 36-year-old woman affected by autoimmune Addison's disease (positive for 21-hydroxylase autoantibodies) and chronic mucocutaneous candidiasis; she is also TPHAbs- without GI symptoms.

All the 16 TPHAbs+ and 2 TPHAbs- APS-1 patients studied by endoscopy were checked for transglutaminase antibodies and all were negative. Of the other 46 patients who did not have endoscopy, 26 were screened and 1 case (TPHAbs-) was found positive for transglutaminase antibodies.

TPHAb

Thirty-seven (57.8%) of the 64 patients with APS-1 were positive for TPHAb. TPHAb positivity was significantly associated with GID: 11/12 (91.7%) patients with GID were positive compared to 26/52 (50%) without GID ($P < .001$). One of 12 patients with GID was TPHAb-. The mean TPHAb index for all positive patients was 102.8 ± 58.1 (mean \pm SD). The mean TPHAb index for patients with GID was 140.8 ± 50.0 (mean \pm SD), whereas for patients without GID it was 89.7 ± 55.6 (mean \pm SD) ($P = .03$). TPHAb were not detected in any of the controls.

Histology of biopsy specimens

Results of histologic examination of the biopsy specimens are shown in Table 2.

A mild to moderate lymphoplasmacytic infiltration was found in the gastric biopsies of all TPHAb+ patients. Inflammatory infiltration was characterized by a mainly CD3+ T-cell lymphocytic infiltrate in both gastric antrum (12/16 patients) and body (11/16 patients) with a variable CD4/CD8 ratio (4/1 to 1/19). CD3+/CD8+ T cells were predominant in the intraepithelial infiltrate (Figure 1A). Scattered CD20+ (B cells) were also found, frequently arranged in clusters (5/16 patients) (not shown).

None of the patients had histologic evidence of pyloric metaplasia, pancreatic acinar cell metaplasia, or enterochromaffin-like cell hyperplasia. A mild active inflammation was observed in the antrum of the H pylori-positive patient (Table 3, patient 16).

Duodenal biopsies were available for 15 TPHAb+ patients and showed a mild lymphocytic infiltration predominantly with CD3+ T cells in 6 of 7 patients with GID (85.7%) and in 4 of 8 patients without GID (50%). In all 10 specimens that showed the signs of lymphocytic infiltrations, an increased population of CD3+CD8+ IELs was also found (Figure 1B).

No other significant histologic changes or enterocyte damage was found in patients who had a duodenal biopsy. The available colonic biopsies showed a mild stromal lymphocyte infiltration with mildly fibrotic features in 2 patients with GID (Table 3, patients 4 and 7), which was unremarkable in the other patient without GID (Table 3, patient 15). The 2 TPHAb- APS-1 patients without GID had a normal gastric and duodenal mucosa, which was comparable with that from the 6 controls samples.

Immunohistochemistry of biopsy specimens and serotonin plasma levels

TPHAb+ patients with GID

The gastric biopsies in all 8 TPHAbs+ patients with GID showed complete absence of serotonin containing EC (Figure 1, D and F). Five of the 7 duodenal biopsies were also negative for EC (Figure 1H) and the other 2 duodenal biopsies showed only a few serotonin-positive cells. The 2 colonic biopsies were also negative for EC (not shown). Results of immunohistochemistry for chromogranin-A on antral, body, and duodenal biopsies are summarized in Table 3.

The mean serotonin plasma level was $0.16 \pm 0.14 \mu\text{mol/L}$ (Table 3 and Figure 2) and was significantly lower ($P < .01$) compared to that found in TPHAbs- controls ($1.01 \pm 0.65 \mu\text{mol/L}$; range 0.33–2.1 $\mu\text{mol/L}$) and to the reference normal range.

TPHAbs+ patients without GID

The antrum biopsies were negative for serotonin by immunohistochemistry in 7 of 8 TPHAbs+ patients without GID, whereas only a few serotonin-producing EC were found in 1 of 8 patients. In the case of gastric body biopsies, there was no detectable reactivity for serotonin in 6 of 8 patients; 1 patient had only a small number of serotonin-positive cells and 1 patient had a normal number of serotonin-positive cells. Duodenal biopsies showed that 2 patients had a normal number of serotonin-positive cells, and 5 patients had lower than normal number, whereas in the case of 1 patient serotonin-positive cells were absent (Table 3, patient 10). Only a few serotonin-positive EC were found on 1 available colonic biopsy. Results of immunostaining for chromogranin-A on gastric and duodenal biopsies are summarized in Table 3.

The mean serotonin plasma level was $0.58 \pm 0.41 \mu\text{mol/L}$ (Table 3 and Figure 2), which was higher than that in TPHAbs+ with the GID group, lower than the control group ($1.01 \pm 0.65 \mu\text{mol/L}$; range 0.33–2.1 $\mu\text{mol/L}$) and within the reference normal range.

TPHAbs- patients

The 2 TPHAbs- APS-1 patients without GID had an immunohistochemical reactivity for serotonin and chromogranin-A comparable with that from the 6 archival samples. Also the serum serotonin levels were within the normal range (Table 3).

Genetic study

Analysis of the AIRE gene revealed the presence of mutations in all the 16 patients who underwent endoscopy (Table 3).

Discussion

In our study of a large group of Italian APS-1 patients, TPHAbs were found in 57.8% of patients. Furthermore, 11 of 12 patients (91.7%) with idiopathic GID were TPHAbs+. These observations are consistent with previous reports based on other groups of patients (9, 10, 28). In addition, our study provides an interesting insight into the relationship between TPHAbs positivity and autoimmune processes affecting the gut mucosa. Evidence of a lymphoplasmacytic infiltration of lamina propria has been found in the GI tract of TPHAbs+ patients, characterized by an increased population of CD3+CD8+ IELs. A gastric infiltration was apparent in all the TPHAbs+ patients studied being present in the gastric antrum and the body (interestingly, this pangastric distribution differs from the classic type A and type B gastritis recognized in the updated Sydney System) (22). Furthermore, in the patients with clinical GID, the inflammatory infiltration extended to the duodenal and colonic mucosa and the intensity of the infiltration was greater in patients with clinical GID compared to TPHAbs+ patients without GID. The observed extensive lymphocytic infiltration in TPHAbs+ patients correlated with a marked reduction in number of EC or with the complete loss of EC throughout the GI tract. The inflammatory infiltration and loss of EC were more extensive in patients with clinical GID who, in addition to the gastric involvement, also showed reduction or absence of serotonin immunoreactivity in the duodenal and the colonic biopsy specimens. In contrast, the inflammatory infiltration and loss of EC were less extensive and prevalently localized in the gastric mucosa of the asymptomatic TPHAbs+ patients. The observed changes affecting EC in TPHAbs+ patients were consistent with reduced immunostaining for chromogranin-A.

Serotonin levels in the peripheral blood are thought to reflect serotonin release from the GI tract (15–20) and in this study we observed that TPHAbs+ patients with GID had mean plasma serotonin levels significantly lower than the normal range (consistent with the loss of EC throughout the GI tract), whereas the TPHAbs+ patients without GID had mean plasma serotonin levels near the lower limit of the normal range (consistent with the incomplete loss of serotonin immunoreactivity in the duodenal and colonic biopsies). This may reflect the autoimmunity related to serotonin-producing EC failure.

In view of the Witebsky criteria (revised by Rose) (29,30) for defining an autoimmune disease, positivity for TPHAbs in APS-1 seems to indicate a distinct GI autoimmune disease targeting gut EC characterized by the following: 1) genetic susceptibility (AIRE gene mutations); 2) lymphocytic infiltration with presence of IELs in the GI tract; and 3) absence of the EC in the gut associated with low plasma serotonin levels.

The natural history of an autoimmune disease often is characterized by progressive phases, usually identified as potential, subclinical, and clinical (7, 31). Similar progressive phases were observed in patients in our study. In particular,

patients with a clinical form (Table 3, patients 1–8) were characterized by genetic predisposition, presence of TPHAbs, clinical GID, diffuse lymphoplasmacytic infiltration in the whole GI tract, absence of EC throughout the GI tract, and low plasma serotonin levels. Patients with a subclinical/preclinical form (Table 3, patients 9–16) were characterized by the presence of TPHAbs, absence of clinical manifestations, variable inflammatory infiltration and EC involvement along the GI tract, and plasma serotonin levels in the lower range of normal values. The potential disease, theoretically, would be characterized by the presence of TPHAbs in the absence of any impairment of the target organ. It is not yet known whether changes in serotonin signaling contribute to the alterations in GI function, but several lines of evidence support the concept that altered serotonin signaling can lead to changes in gut function. Studies on diarrhea-predominant irritable bowel syndrome and constipation-predominant irritable bowel syndrome report changes in 1 or more aspects of serotonin signaling in both senses, increased or decreased function (16, 19, 32, 33). Also on inflammatory bowel disease altered serotonin physiology is reported but without univocal results (32, 34–36). Due to the complex interactions (15) between substances released by enteroendocrine cells, cytokines released by local and remote immunologically reactive cells, the activity of the enteric nervous system, the peripherally released peptides and hormones, and the serotonergic signaling, it would be very difficult to predict the effect of the complete or partial loss of EC on GI function, and whether this loss would have a stimulatory or an inhibitory effect. All these components may influence gut physiology. Probably also individual genetic and epigenetic factors (ie, serotonin receptors or serotonin-selective reuptake transporter expressions) contribute to determine the clinical phenotype (37, 38). Further studies are needed to explain these mechanisms and clarify why in APS-1 patients the GID is reported as both diarrhea and constipation.

Treatment options for TPHAbs+ patients with GID present an interesting challenge. As the changes in serotonergic signaling are believed to stem from an autoimmune attack, immunosuppression may well be the most appropriate choice of treatment, as suggested previously (39, 40). However, autoimmune diseases in APS-1 are mostly related to T-cell dysregulation and, although the autoantibodies do not appear to have a directly pathogenic role, they are important hallmarks of the disease and usually have value for diagnosis and prediction of the disease. However, recently the importance of the B cells' involvement has been highlighted in the induction of organ-specific autoimmunity in the mouse model of APS-1 (41) and in the human pulmonary component of APS-1 (42): a good response to Rituximab immunotherapy in both situations raises the possibility of proposing similar treatment options also in TPHAbs+ patients with severe GID. Screening for TPHAbs could identify a subset of APS-1 patients with, or that can potentially develop if asymptomatic, GID of autoimmune etiology. The positivity needs to be confirmed by a subsequent serum

serotonin evaluation and coherent histologic and immunohistochemical findings on GI endoscopy to define the disease's stage and to rule out other autoimmune or nonautoimmune GI diseases. In the case of an absence/marked depletion of EC, an immunosuppressive therapy could be considered in addition to standard supportive care. This strategy would lead to early diagnosis and timely treatment of patients with GID because of an autoimmune reaction to EC. Serum serotonin level by itself is not specific because it can be altered in other conditions (16, 19, 32–36) and it could be useful to measure it to evaluate the treatment's response without performing endoscopy, or when it cannot be performed. Finally, TPHAbs positivity could alert the clinician to APS-1 in patients who present with GID symptoms in the absence of other components of the syndrome.

Acknowledgments

Address all correspondence and requests for reprints to: Corrado Betterle, MD, Endocrine Unit, Department of Medicine, Via Ospedale Civile 105, 35128, Padova, Italy. E-mail: corrado.betterle@unipd.it.

This study was supported in part by a grant from the European Union Sixth Framework Programme, the EurAPS project: Autoimmune Polyendocrine Syndrome type I—a rare disorder of childhood as a model for autoimmunity, contract number 2005-005223, and in part by a grant from the European Union Seventh Framework Programme, the EurAdrenal project: Pathophysiology and Natural Course of Autoimmune Adrenal Failure in Europe, contract number 2008-201167.

Disclosure Statement: J.F., S.C., and B.R.S. are employed by RSR Ltd. RSR Ltd is a developer of medical diagnostics, including kits for measuring tryptophan hydroxylase autoantibodies.

References

1. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, et al. Positional cloning of the APECED gene. *Nat Genet.* 1997;17: 393–398.
2. The Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. *Nat Genet.* 1997;17:399 – 403.
3. Mathis D, Benoist C AIRE. *Annu Rev Immunol.* 2009;27:287–312.
4. Betterle C, Greggio NA, Volpato M. Autoimmune polyglandular syndrome type 1. *J Clin Endocrinol Metab.* 1998;83:1049 –1055.

5. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. *J Clin Endocrinol Metab.* 2006;91:2843–2850.
6. Husebye ES, Perheentupa J, Rautemaa R, Kämpe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. *J Intern Med.* 2009;265:514–529.
7. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. *Endocr Rev.* 2002;23:327–364.
8. Hogenauer C, Meyer R, Netto GJ, Bell D, Little KH, Ferries L, et al. Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I. *N Engl J Med.* 2001; 344:270–274.
9. Ekwall O, Hedstrand H, Grimelius L, Haavik J, Perheentupa J, Gustafsson J, et al. Identification of tryptophan hydroxylase as an intestinal autoantigen. *Lancet.* 1998;352:279–283.
10. Dal Pra C, Chen S, Betterle C, Zanchetta R, McGrath V, Furmaniak J, et al. Autoantibodies to human tryptophan hydroxylase and aromatic L-amino acid decarboxylase. *Eur J Endocrinol.* 2004;150: 313–321.
11. De Luca F, Valenzise M, Alaggio R, Arrigo T, Crisafulli G, Salzano G, et al. Sicilian family with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and lethal lung disease in one of the affected brothers. *Eur J Pediatr.* 2008;167:1283–1288.
12. Gianani R, Eisenbarth GS. Autoimmunity to gastrointestinal endocrine cells in autoimmune polyendocrine syndrome type I. *J Clin Endocrinol Metab.* 2003;88:1442–1444.
13. Mirakian R, Locatelli M, Bottazzo F. Disclosure of novel autoantigens in human autoimmunity. *Lancet.* 1998;352:255–256.
14. Boadle-Biber MC. Regulation of serotonin synthesis. *Prog Biophys Mol Biol.* 1993;60:1–15.
15. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. *Gastroenterology.* 2007;132:397–414.
16. Bearcroft CP, Perrett D, Farthing MJG. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. *Gut.* 1998;42:42–46.
17. Morrissey JJ, Walker MN, Lovenberg W. The absence of tryptophan hydroxylase activity in blood platelets. *Proc Soc Exp Biol Med.* 1977;154:496–499.

18. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. *Gut*. 2003; 52:663–670.
19. Dunlop SP, Coleman NS, Blackshaw PE, Perkins AC, Singh G, Marsden CA, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. *Clin Gastroenterol Hepatol*. 2005;3:349–357.
20. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. *Gastroenterology*. 2006;130:34–43.
21. Posovszky C, Lahr G, von Schnurbein J, Buderus S, Findeisen A, Schroder C, et al. Loss of Enteroendocrine cells in autoimmune-polyendocrine-candidiasis-ectodermal-dystrophy (APECED) syndrome with gastrointestinal dysfunction. *J Clin Endocrinol Metab*. 2012;97:292–300.
22. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol*. 1996;20:1161–1181.
23. Kakar S, Nehra V, Murray JA, Dayharsh GA, Burgart LJ. Significance of intraepithelial lymphocytosis in small bowel biopsy samples with normal mucosal architecture. *Am J Gastroenterol*. 2003; 98:2027–2033.
24. Ohsie S, Gerney G, Gui D, Kahana D, Martín MG, Cortina G. A paucity of colonic enteroendocrine and/or enterochromaffin cells characterizes a subset of patients with chronic unexplained diarrhea/malabsorption. *Hum Pathol*. 2009;40:1006–1014.
25. Cortina G, Smart CN, Farmer DG, Bhuta S, Treem WR, Hill ID, et al. Enteroendocrine cell dysgenesis and malabsorption, a histopathologic and immunohistochemical characterization. *Hum Pathol*. 2007;38:570–580.
26. Picard M, Olichon D, Gombert J. Determination of serotonin in plasma by liquid chromatography with electrochemical detection. *J Chromatogr*. 1985;341:445–451.
27. Cervato S, Mariniello B, Lazzarotto F, Morlin L, Zanchetta R, Raddetti G, et al. Evaluation of the autoimmune regulator (AIRE) gene mutations in a cohort of Italian patients with autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) and in their relatives. *Clin Endocrinol (Oxf)*. 2009;70:421–428.
28. Søderbergh A, Myhre AG, Ekwall O, Gebre-Medhin G, Hedstrand H, Landgren E, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. *J Clin Endocrinol Metab*. 2004;89:557–562.
29. Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW. Chronic thyroiditis and autoimmunization. *J Am Med Assoc*. 1957;164: 1439–1447.

30. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). *Immunol Today*. 1993;14:426–430.
31. Michels AW, Eisenbarth GS. Immunologic endocrine disorders. *J Allergy Clin Immunol*. 2010;125(2 suppl 2):S226–S237.
32. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. *Gastroenterology*. 2004;126:1657–1664.
33. Miwa J, Echizen H, Matsueda K, Umeda N. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. *Digestion*. 2001;63:188–194.
34. Magro F, Vieira-Coelho MA, Fraga S, Serrão MP, Veloso FT, Ribeiro T, et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. *Dig Dis Sci*. 2002;47:216–224.
35. Ahonen A, Kyosola K, Penttilä O. Enterochromaffin cells in macrophages in ulcerative colitis and irritable colon. *Ann Clin Res*. 1976;8:1–7.
36. El-Salhy M, Danielsson A, Stenling R, Grimelius L. Colonic endocrine cells in inflammatory bowel disease. *J Intern Med*. 1997;242: 413–419.
37. Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. *Mol Interv*. 2004; 4:109–123.
38. Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. *Gut*. 2004;53:1452–1458.
39. Ward L, Paquette J, Seidman E, Huot C, Alvarez F, Crock P, et al. Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. *J Clin Endocrinol Metab*. 1999;84:844–852.
40. Padeh S, Theodor R, Jonas A, Passwell JH. Severe malabsorption in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome successfully treated with immunosuppression. *Arch Dis Child*. 1997;76:532–534.
41. Gavanescu I, Benoist C, Mathis D. B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: a therapeutic approach for APECED patients. *Proc Natl Acad Sci USA*. 2008;105:13009–13014.

42. Popler J, Alimohammadi M, Kämpfe O, Dalin F, Dishop MK, Barker JM, et al. Autoimmune polyendocrine syndrome type 1: utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. *Pediatr Pulmonol.* 2012; 47:84 – 87.

Table 1. Clinical Manifestation in the 64 APS-1 Patients and in the 16 TPHAbs+ Patients at Inclusion

	Manifestations	Prevalence (%) in	
		64 APS-1 Patients	16 Patients Investigated by Endoscopy
Main components	Addison's disease	53 (82.8)	16 (100.0)
	Chronic hypoparathyroidism	61 (95.3)	16 (100.0)
	Chronic candidiasis	55 (85.9)	14 (87.5)
Other components	Ectodermal manifestation (ocular, skin and nail manifestations)	28 (43.8)	6 (37.5)
	Autoimmune thyroid diseases	21 (32.8)	6 (37.5)
	Hypergonadotropic hypogonadism	19 (29.7)	6 (37.5)
	Autoimmune gastritis	23 (35.9)	6 (37.5)
	Pernicious anemia	13 (20.3)	7 (43.7)
	Autoimmune hepatitis	14 (21.9)	9 (56.2)
	Gastrointestinal dysfunction	12 (18.8)	8 (50.0)
	Alopecia	20 (31.3)	7 (43.7)
	Vitiligo	14 (21.9)	7 (43.7)
	Diabetes mellitus (type 1)	4 (6.3)	1 (6.2)
	Pituitary failure	5 (7.8)	1 (6.2)

Table 2. Histological Findings in TPHAbs+ Patients

Site	Histological Feature	Prevalence (%) in		
		TPHAb+	TPHAb+ With GID	TPHAb+ Without GID
Antrum		16 cases	8 cases	8 cases
	Lymphoplasmacytic infiltrate	16/16 (100)	8/8 (100)	8/8 (100)
	Increased IELs	13/16 (81.3)	8/8 (100)	5/8 (62.5)
	Atrophy	0/16	0/8	0/8
	Intestinal metaplasia	1/16 (6.3)	0/8	1/8 (12.5)
Gastric body	Regenerative hyperplasia	6/16 (37.5)	3/8 (37.5)	3/8 (37.5)
		16 cases	8 cases	8 cases
	Lymphoplasmacytic infiltrate	16/16 (100)	8/8 (100)	8/8 (100)
	Increased IELs	12/16 (75.0)	8/8 (100)	4/8 (50.0)
	Atrophy	6/16 (37.5)	3/8 (37.5)	3/8 (37.5)
Duodenum	Intestinal metaplasia	3/16 (18.8)	1/8 (12.5)	2/8 (25.0)
	Regenerative hyperplasia	4/16 (25.0)	2/16 (12.5)	2/16 (12.5)
		15 cases	7 cases	8 cases
	Lymphoplasmacytic infiltrate	10/15 (66.7)	6/7 (85.7)	4/8 (50.0)
	Increased IELs	10/15 (66.7)	6/7 (85.7)	4/8 (50.0)
	Villus atrophy	0/15	0/7	0/8
	Crypt hyperplasia	0/15	0/7	0/8
	fibrosis	0/15	0/7	0/8

Table 3. Immunohistochemical, Genetic, and Serologic Findings in TPHAbs+ Patients

Patient No.	TPHAb Index	GI Dysfunction	AIRE Gene Mutations	Gastric EC ^a (Antrum/Body)	Duodenal EC ^a	Serotonin (0.28–1.7 μmol/L)	Gastric CGA+ Cells ^a (Antrum/Body)	Duodenal CGA+ Cells ^a
1	163.4	Constipation	R257X/R257X	0/0	0	<0.02	0/0	0
2	176.3	Constipation	R203X/R203X	0/0	0	0.12	130/44	45
3	116.4	Constipation	P252L/W78R	0/0	0	0.20	0/0	0
4	96.7	Diarrhea	R257X/R257X	0/0	0	0.39	18/0	3
5	238	Diarrhea	R257X/R203X	0/0	0	<0.02	nt/nt	nt
6	128.5	Diarrhea	IVS1 + 1G>C + 5delG	0/0	nt	<0.02	0/0	nt
7	94.5	Constipation	R203X/R203X	0/0	8	0.16	24/131	48
8	162.4	Diarrhea	W78R/W78R	0/0	4	0.35	nt/nt	nt
Mean ± SD	147.0 ± 45.0					0.16 ± 0.14		
9	148.5	No	R257X/R257X	0/0	9	1.2	39/62	5
10	101.3	No	R257X/R257X	0/0	0	0.31	0/58	88
11	205.2	No	R257X/R203X	0/0	6	0.03	nt/nt	nt
12	135.6	No	del GT/del 13	0/0	2	0.42	117/6	34

13	91.3	No	R257X/G227	0/0	4	1.21	5/0	2
14	129.3	No	del 13/del 13	0/0	3	0.58	0/0	5
15	83.6	No	R257X/R257X	0/24	18	0.17	0/0	10
16	74.4	No	del 13/del 13	8/6	57	0.68	108/282	73
Mean \pm SD	121.2 \pm 40.3					0.58 \pm 0.41		
17	neg	No	R257X/C322X	22/17	77	0.38	81/65	128
18	neg	No	W78R/W78R	12/49	63	1.13	nt/nt	nt
Control group (6 cases)	neg	No	Mean \pm SD	27 \pm 9 16 \pm 8	66 \pm 19		63 \pm 36 80 \pm 46	94 \pm 43

Abbreviations: GI, gastrointestinal; neg, negative; nt, not tested.

^a Results are expressed as number of positive cells per 50 crypts




Figure 1. Immunohistochemistry of antral gastric mucosa [A: CD8 (x320)] and duodenal mucosa [B: CD8 (x320)] showing increased CD8+ T cells in the intraepithelial infiltrate. Serotonin staining of normal gastric antral (C), body (E), and duodenal (G) mucosa showing a normal distribution of EC within the glands, within the crypts, and along the villous surface (x160). Serotonin staining of gastric antrum (D), body (F), and duodenum (H) of TPHAbs+ patient with GID (x160): the gastric glands, duodenal crypt, and villus architecture are normal; however, there is a severe and almost complete loss of EC.

Figure 2. Serotonin serum levels in the 16 TPHAbs+ patients who had endoscopy (8 with GID and 8 without GID) and in 10 TPHAbs- controls without GID. \bar{X} indicates the value in each patient. Broken line shows cutoff value for normal range (0.28 $\mu\text{mol/L}$) and \bar{f} indicates mean value in each subgroup. In TPHAbs+ patients with GID mean serum level was significantly lower than controls and normal range, whereas in patients without GID was within the reference normal range and lower than controls.

